Asclera
Asclera Uses, Dosage, Side Effects, Food Interaction and all others data.
Asclera is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Asclera has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Asclera has a concentration and volume dependent damaging effect on the blood vessel endothelium.
Trade Name | Asclera |
Availability | Prescription only |
Generic | Polidocanol |
Polidocanol Other Names | Aethoxy-sklerol, Laureth 9, Laureth-9, Macrogol 9 lauryl ether, Nonaethylene glycol monododecyl ether, Nonaethylene glycol monolauryl ether, PEG-9 lauryl ether, Polidocanol, Polydocanol, Polyoxyl 9 lauryl ether |
Related Drugs | Asclera, Sotradecol |
Type | Injection, solution |
Formula | C30H62O10 |
Weight | Average: 582.8073 Monoisotopic: 582.434298204 |
Protein binding | Plasma protein binding was not measured. |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | United States, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Asclera is a sclerosing agent used for the treatment of uncomplicated spider veins and uncomplicated reticular veins, all less than 3 mm in diameter, in the lower extremity.
Asclera is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
Asclera is also used to associated treatment for these conditions: Pain caused by Teething, Incompetent accessory saphenous veins, Incompetent great saphenous veins, Superficial venous incompetence, Uncomplicated veins 1 to 3 mm in diameter reticular veins, Uncomplicated veins <1 mm in diameter Spider Veins, Varicosities of the great saphenous vein
How Asclera works
When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.
Toxicity
Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.
Food Interaction
No interactions found.Asclera Disease Interaction
Volume of Distribution
When given intravenously, the volume of distribution was 35-82L.
Elimination Route
When given intravenously, the maximum blood concentrations were reached in 15 mins.
Half Life
The half-life is approximately 1.5 h.
Clearance
Sytemic clearance was 0.2-0.4 L/min.
Elimination Route
Route of elimination was not indicated.
Innovators Monograph
You find simplified version here Asclera